Every Form 4 that Immunitybio Inc (IBRX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow IBRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IBRX filings page.
ImmunityBio, Inc. director Cheryl Cohen reported an exercise-and-sale transaction involving the company’s common stock. On 2026-07-02, she sold 131,210 shares in an open‑market transaction at a weighted average price of $9.5034 per share, under a pre‑arranged Rule 10b5-1 trading plan.
On the same date, Cohen exercised stock options to acquire 55,979 common shares at an exercise price of $2.98 per share, reducing her option position while increasing her direct shareholdings before the sale. Following these transactions, she directly holds 125,386 common shares and 111,958 stock options.
ImmunityBio director Christobel Selecky exercised stock options and sold the resulting shares. She exercised options covering 124,414 shares at $2.99 per share and 35,064 shares at $2.98 per share, then sold 159,478 shares of Common Stock in open-market transactions at a weighted average price of $9.0236 per share, within a range of $9.00 to $9.07. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2026. After these transactions, the filing shows she holds no remaining common shares or related options.
ImmunityBio, Inc. director Christobel Selecky exercised stock options and sold the resulting shares in pre-planned trades. On June 29–30, 2026, she exercised options for a total of 96,722 shares of Common Stock at exercise prices between $2.84 and $2.99 per share and sold 96,722 shares in open-market transactions, including 95,722 shares at a weighted-average price of $9.0075 and 1,000 shares at $9.00 per share.
The sales were made under a Rule 10b5-1 trading plan adopted on March 13, 2026, indicating they were pre-scheduled rather than discretionary. Following these transactions, Selecky reported no directly held Common Stock, while retaining stock options to purchase additional shares at the disclosed exercise prices and expiration dates.
ImmunityBio, Inc. director Barry J. Simon reported an open-market sale of common stock. On June 24, 2026, he sold 25,000 shares at a weighted average price of $7.8763 per share, in a trade executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 18, 2025. After this transaction, he continues to hold 2,802,788 shares of ImmunityBio common stock directly.
ImmunityBio director Michael D. Blaszyk received a grant of stock options covering 65,600 shares of common stock. The options have an exercise price of $7.25 per share and expire on June 9, 2036.
According to the award terms, subject to his continuing to be a Service Provider under ImmunityBio’s 2025 Equity Incentive Plan, 100% of the shares subject to the option will vest on the earlier of June 9, 2027 or the date immediately before the next annual stockholder meeting.
ImmunityBio director Wendel Bruce received a new stock option grant as part of his compensation. He was awarded options covering 65,600 shares of ImmunityBio common stock at an exercise price of $7.25 per share, with no cash paid at grant.
These options vest 100% on the earlier of June 9, 2027 or the date immediately before the next annual stockholder meeting, as long as he continues as a service provider under the company’s 2025 Equity Incentive Plan. The options expire on June 9, 2036, giving a long-term incentive tied to the company’s share price.
ImmunityBio director Linda Maxwell received a grant of stock options covering 65,600 shares of Common Stock. The options have an exercise price of $7.25 per share and expire on June 9, 2036.
All 65,600 shares subject to the award will vest in a single tranche, provided she continues as a “Service Provider” under the company’s 2025 Equity Incentive Plan, on the earlier of June 9, 2027 or the date immediately preceding the next annual meeting of stockholders. Following this award, she holds 65,600 options directly.
ImmunityBio director Wesley Clark received a new stock option grant. The award covers 65,600 shares of Common Stock at an exercise price of $7.25 per share and expires on June 9, 2036. All 65,600 options vest 100% on the earlier of June 9, 2027 or the date immediately before the next annual stockholder meeting, if he continues as a service provider.
ImmunityBio director Cheryl Cohen received a new stock option grant. She was awarded options to buy 65,600 shares of ImmunityBio common stock at an exercise price of $7.25 per share, expiring on June 9, 2036. This is a compensation-related award, not an open-market purchase.
The option vests in full only if she continues as a service provider. All 65,600 shares underlying the award will vest on the earlier of June 9, 2027 or the date immediately before the next annual meeting of stockholders. Following this grant, she holds 65,600 stock options directly.
ImmunityBio, Inc. director Christobel Selecky received a grant of stock options covering 65,600 shares of common stock. The options have an exercise price of $7.25 per share and expire on June 9, 2036.
Subject to Selecky continuing as a “Service Provider” under the company’s 2025 Equity Incentive Plan, 100% of the options will vest on the earlier of June 9, 2027 or the date immediately preceding the next annual meeting of stockholders. Following this grant, Selecky holds 65,600 stock options directly.
ImmunityBio director Barry J. Simon reported an open-market sale of 23,033 shares of Common Stock at a weighted average price of $7.1769 per share. The sale was executed on June 4, 2026 under a pre-arranged Rule 10b5-1 trading plan. After the transaction, he directly holds 2,827,788 shares.
ImmunityBio, Inc. reported that Nant Capital, LLC, an investment vehicle affiliated with Patrick Soon-Shiong, converted $25,000,000 of a Second Amended and Restated Convertible Promissory Note into 4,606,596 shares of common stock at $5.427 per share on March 31, 2026.
Following this derivative conversion, entities associated with Soon-Shiong indirectly held 251,018,873 shares of ImmunityBio common stock, and he also directly held 29,757,911 shares. The filing shows his influence through multiple affiliated entities with voting and dispositive power over these holdings.
ImmunityBio director Barry J. Simon reported an open-market sale of common stock. On this Form 4, he sold 75,000 shares of ImmunityBio, Inc. common stock in an open-market transaction at a weighted average price of $12.0105 per share.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 4, 2024. After this sale, Simon directly holds 2,850,821 shares of ImmunityBio common stock, according to the filing.
ImmunityBio, Inc. director Christobel Selecky reported an option exercise and share sale. On February 23, 2026, she exercised a stock option for 25,000 shares, acquiring an equal number of ImmunityBio common shares at a price of $2.98 per share through the derivative conversion. A related option line shows 25,000 stock option rights exercised, with 67,937 options remaining directly owned after the transaction. On the same date, she then sold 25,000 common shares at $10.00 per share, leaving 0 shares from that lot directly owned after the sale. The sale was carried out under a Rule 10b5-1 trading plan adopted on June 12, 2025, and all shares underlying the option had fully vested on June 12, 2023.
ImmunityBio, Inc. Chief Financial Officer David C. Sachs reported the vesting and settlement of restricted stock units. On February 22, 2026, 40,650 RSUs were exercised into the same number of common shares at $0.00 per share. To cover tax withholding, 20,682 common shares were automatically disposed of at $8.70 per share, a price based on the February 20, 2026 closing price. After these transactions, Sachs directly held 300,143 shares of common stock and 40,651 restricted stock units, reflecting routine equity compensation vesting rather than an open‑market trade.
ImmunityBio director and major holder Patrick Soon-Shiong reported vesting of restricted stock units and related share movements. On February 22, 2026, 114,329 restricted stock units were exercised into an equal number of common shares at $0.00 per share. To cover tax obligations, 58,170 common shares were disposed of at $8.70 per share through share withholding, leaving 29,757,911 common shares held directly after these transactions. Additional large blocks of ImmunityBio common stock are reported as held indirectly through affiliated entities such as Nant Capital, Cambridge Equities, NantBio, California Capital Equity, the Chan Soon-Shiong Family Foundation, NantWorks, NantMobile, and NantCancerStemCell, over which the reporting person may be deemed to have voting and dispositive power as described in the footnotes.
ImmunityBio, Inc. Chief Accounting Officer Regan J. Lauer reported vesting of 4,065 restricted stock units (RSUs) on February 22, 2026. Each RSU converts into one share of common stock, so 4,065 shares were acquired at a stated price of $0.00 per share.
To satisfy tax obligations from this vesting, 1,673 common shares were disposed of at $8.70 per share through share withholding, rather than an open-market sale. After these transactions, Lauer directly owns 115,875 shares of ImmunityBio common stock.
ImmunityBio, Inc. director, CEO and President Richard Adcock reported equity award activity involving restricted stock units (RSUs) and common stock. On February 22, 2026, 152,439 RSUs were exercised or converted into 152,439 shares of common stock at a price of $0.00 per share, reflecting vesting of a prior RSU grant.
In a related tax-withholding transaction, 77,560 shares of common stock were disposed of at $8.70 per share to cover tax obligations associated with the RSU vesting, rather than an open-market sale. Following these transactions, Adcock directly held 560,344 shares of ImmunityBio common stock. Footnotes explain that each RSU represents a right to receive one share of common stock and outline a three-year vesting schedule that began on February 22, 2024, conditioned on continued service.
ImmunityBio director Barry J. Simon reported a mix of stock sales and equity awards for ImmunityBio, Inc. common stock. He sold 165,000 shares on February 23, 2026 in open-market transactions at a weighted average price of $10.2491 per share under a Rule 10b5-1 trading plan, and sold another 10,000 shares on February 20, 2026 at $9.25 per share. On February 22, 2026, restricted stock units representing 15,243 shares vested and were converted into common stock at no cost, with 6,026 shares withheld at $8.70 per share to cover taxes. After these transactions, he directly owned 2,925,821 shares of ImmunityBio common stock.
ImmunityBio, Inc. insider activity: Patrick Soon-Shiong and affiliated entities reported equity award vesting and related share movements. On February 10, 2026, 274,122 restricted stock units were converted into an equal number of ImmunityBio common shares at an exercise price of $0.00. To cover tax obligations on this vesting, 118,560 common shares were withheld at a price of $6.93 per share. Following these transactions, Soon-Shiong directly held 29,701,752 common shares. The filing also lists very large indirect holdings through entities such as Nant Capital, Cambridge Equities, NantBio, California Capital Equity, the Chan Soon-Shiong Family Foundation, NantWorks, NantMobile and NantCancerStemCell, over which he is described as having varying degrees of voting and dispositive power.
ImmunityBio, Inc. Chief Financial Officer David C. Sachs reported RSU vesting and related share withholding. On February 10, 2026, 82,236 restricted stock units converted into 82,236 shares of common stock at an exercise price of $0, increasing his directly held common stock to 322,818 shares.
On the same date, 42,643 common shares were disposed of at $6.93 per share to cover tax obligations tied to the RSU vesting, leaving him with 280,175 common shares held directly after these transactions. Following the vesting, he also held 164,474 RSUs directly.
ImmunityBio, Inc.’s Chief Accounting Officer, Regan J. Lauer, reported RSU vesting and related share movements. On February 10, 2026, 5,482 restricted stock units were converted into 5,482 shares of common stock at an exercise price of $0, increasing directly held common shares to 115,740.
On the same date, 2,257 common shares were withheld at $6.93 per share to cover tax obligations tied to the vesting, leaving 113,483 common shares held directly after the withholding. Following these transactions, Lauer also directly held 10,965 restricted stock units, which vest over three years starting from a February 10, 2025 commencement date.
ImmunityBio, Inc. executive Richard Adcock, the CEO and President, reported equity compensation activity involving restricted stock units (RSUs) and common stock. On February 10, 2026, 274,122 RSUs were converted into the same number of common shares at an exercise price of $0, reflecting vesting of a prior RSU grant.
To cover tax obligations from this vesting, 140,048 common shares were withheld and disposed of at a price of $6.93 per share. After these transactions, Adcock beneficially owned 485,465 shares of ImmunityBio common stock directly, along with 548,246 RSUs that remain outstanding as derivative securities. The RSU award vests over three years from a vesting commencement date of February 10, 2025, contingent on continued service.
ImmunityBio, Inc. director Simon Barry J. reported two open-market sales of common stock. On January 20, 2026, he sold 76,967 shares at $6.54 per share and 75,000 shares at a weighted average price of $7.8791 per share. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 4, 2024. Following the reported sales, he directly beneficially owned 3,091,604 shares of ImmunityBio common stock.
ImmunityBio, Inc. director Christobel Selecky reported option exercises and share sales in January 2026. On January 16, 2026, she exercised 50,000 stock options with a $2.98 exercise price for common stock and then sold 50,000 shares at $5.00 per share, leaving her with no directly held common stock after the sale. On January 20, 2026, she exercised an additional 25,000 stock options at $2.98 and sold 25,000 shares at a weighted average price of $7.50 to $7.52, again ending with no directly held common shares.
The Form 4 shows that after these transactions, she continued to hold stock options, with 117,937 options remaining after the first exercise and 92,937 options after the second. All of the option shares had fully vested on June 12, 2023, and the options are scheduled to expire on June 14, 2032. The filing notes that the reported sales were made under a Rule 10b5-1 trading plan that she adopted on June 12, 2025, indicating the transactions were pre-arranged rather than opportunistic.
ImmunityBio, Inc. director reported receiving a new stock option grant for 146,020 shares of common stock at an exercise price of $2.36 per share, expiring on December 12, 2035.
The award was granted under the 2025 Equity Incentive Plan and vests in three annual installments, with 48,673 options vesting on December 12, 2026, 48,673 on December 12, 2027 and 48,674 on December 12, 2028, as long as the director continues as a service provider.
Any unvested options will fully vest immediately before a Change in Control, as defined in the 2025 Equity Incentive Plan, if the director remains a service provider through that date.